Clinical Trial Update: A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluate the efficacy and safety of Fruquintinib (HMPL-013) in metastatic colorectal/colon cancer, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Metastatic Colorectal Cancer, Metastatic Colon Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-09-14